{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T07:18:37Z","timestamp":1781939917550,"version":"3.54.5"},"reference-count":34,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2004,10,29]],"date-time":"2004-10-29T00:00:00Z","timestamp":1099008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2004,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold><jats:sc>objective\u2002<\/jats:sc><\/jats:bold> Following a successful clinical trial in 1996, the long\u2010acting GnRH analogue goserelin (Zoladex LA 10\u00b78\u00a0mg; Astra Zeneca) has been our preferred treatment for central early (CEP) or precocious puberty (CPP). However, some female patients have expressed concern about perceived weight gain during therapy and delay in the onset or resumption of menses on completion of therapy. The primary aim of this study was to investigate these concerns by determining the auxological parameters and timing of menarche or re\u2010menarche in all girls with CEP\/CPP who have completed a course of Zoladex LA treatment. The secondary aim was to assess auxological outcome in girls who have attained final height.<\/jats:p><jats:p><jats:bold><jats:sc>design and patients\u2002<\/jats:sc><\/jats:bold> Case records of all girls with idiopathic CEP\/CPP or CEP\/CPP secondary to CNS pathology treated with Zoladex LA since 1996 were reviewed. A total of 46 girls who have completed therapy were identified, of whom 11 had reached final height.<\/jats:p><jats:p><jats:bold><jats:sc>measurements\u2002<\/jats:sc><\/jats:bold> Height, weight and bone age (RUS (TW2) method) were measured before treatment, when Zoladex LA was stopped and at final height. Body mass index (BMI) was calculated as a clinical measure of body fatness. Pubertal status was assessed pre\u2010 and post\u2010treatment by Tanner staging and pelvic ultrasonography. Timing of menarche or re\u2010menarche following cessation of treatment was recorded.<\/jats:p><jats:p><jats:bold><jats:sc>results\u2002<\/jats:sc><\/jats:bold> The mean (range) age of starting GnRH analogue therapy was 8\u00b73\u00a0(1\u00b78\u201310\u00b75)\u00a0years and the duration of treatment was 2\u00b79\u00a0(0\u00b77\u20138\u00b79)\u00a0years. Pre\u2010treatment height was above average at 0\u00b772\u00a0SD but had declined to 0\u00b728\u00a0SD by the end of therapy. The 46 girls were heavier than average before treatment (Wt\u00a0SDS\u00a01\u00b704) with no change in weight status on completion of therapy. Mean BMI\u00a0SDS increased significantly from 0\u00b793 to 1\u00b72 during treatment, indicating that the girls became relatively fatter. Using recommended BMI cut\u2010off values for defining overweight and obesity in children of the 85th and 95th centiles, 41% of the cohort were overweight and 28% were obese before treatment, rising to 59% and 39%, respectively, at the end of therapy. The average time interval to onset or resumption of menses after stopping treatment was 1\u00b746\u00a0years (median 1\u00b75, range 0\u00b78\u20132\u00b70\u00a0years). None of the following variables was found to be predictive of the time interval to menarche after completion of therapy: duration of treatment; chronological age; bone age; Tanner breast stage or uterine maturation at the end of treatment; the frequency of injections required to suppress puberty; or treatment with alternative GnRH analogue prior to Zoladex LA. Mean final height in 11 girls was 159\u00b77\u00a0cm (\u22120\u00b763\u00a0SD), close to the mean parental target height of 160\u00b79\u00a0cm (\u22120\u00b748\u00a0SD). Nine of the 11 girls (82%) attained final heights within or above their target range. In keeping with the whole cohort this subset of girls became fatter during treatment, although this difference was not statistically significant. However, they returned to their pretreatment size at final height (mean BMI\u00a0SDS 1\u00b718, 1\u00b741 and 1\u00b716 before, at the end of treatment and at final height, respectively).<\/jats:p><jats:p><jats:bold><jats:sc>conclusions\u2002<\/jats:sc><\/jats:bold> Our cohort of 46 girls treated with long\u2010acting goserelin was already considerably overweight at the start of therapy and became fatter during treatment. However, adiposity appeared to return to pretreatment levels in the 11 girls followed up to final height. Most of the girls who have attained final height are within or above their expected target range. The relatively long time interval to menarche of 1\u00b75\u00a0years after stopping treatment is unexplained but may reflect a residual suppressive effect on the hypothalamo\u2013pituitary axis of this long\u2010acting GnRH analogue. Anticipation of the timing of menarche has proved to be of value in planning when to stop therapy in girls in whom treatment is mainly for practical and\/or psychological reasons.<\/jats:p>","DOI":"10.1111\/j.1365-2265.2004.02146.x","type":"journal-article","created":{"date-parts":[[2004,11,2]],"date-time":"2004-11-02T12:47:32Z","timestamp":1099399652000},"page":"626-634","source":"Crossref","is-referenced-by-count":59,"title":["Auxological outcome and time to menarche following long\u2010acting goserelin therapy in girls with central precocious or early puberty"],"prefix":"10.1111","volume":"61","author":[{"given":"W. F.","family":"Paterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"McNeill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. D. C.","family":"Donaldson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,10,29]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)92552-8"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2002.01488.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.2000.13.S1.773"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.102.3.e29"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.10.3575"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003081-199309000-00033"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1998.tb00921.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2001-020243"},{"key":"e_1_2_6_10_1","first-page":"653","article-title":"Long\u2010term effectiveness of depot gonadotropin\u2010releasing hormone analogue in the treatment of children with central precocious puberty","volume":"147","author":"Clemons R.D.","year":"1993","journal-title":"American Journal of Diseases of Children"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.73.1.25"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-52-2-370"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(98)70426-3"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.1.5409"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.73.1.17"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1995.tb13689.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.12.4583"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.75.3.890"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000181437"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.2000.13.S1.765"},{"key":"e_1_2_6_21_1","unstructured":"NHS Quality Improvement Scotland:Clinical Outcomes Indicators.Clinical Outcomes Group November 2003. ISBN 1\u201084404\u2010200\u20106.http:\/\/www.nhshealthquality.org."},{"key":"e_1_2_6_22_1","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1210\/jcem.86.10.7915","article-title":"Increased final height in precocious puberty after long\u2010term treatment with LHRH agonists: The National Institutes of Health Experience","volume":"86","author":"Oerter Klein K.","year":"2001","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.75.4.292"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.12.4480"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1515\/JPEM.2000.13.S1.747"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.79.4.323"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.2.546"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(98)70433-0"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)04555-9"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.5.1696"},{"key":"e_1_2_6_31_1","volume-title":"Growth at Adolescence","author":"Tanner J.M.","year":"1962"},{"key":"e_1_2_6_32_1","volume-title":"Assessment of Skeletal Maturity and Prediction of Adult Height (TW2 Method)","author":"Tanner J.M.","year":"1983"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.87.2.506"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199141050-00004"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.72.1.38"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2004.02146.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2004.02146.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T19:14:33Z","timestamp":1697224473000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2004.02146.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,29]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["10.1111\/j.1365-2265.2004.02146.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2004.02146.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,29]]}}}